NextCure, Inc. (NASDAQ:NXTC) Short Interest Update

NextCure, Inc. (NASDAQ:NXTC) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 41,200 shares, a decrease of 56.6% from the December 31st total of 94,900 shares. Based on an average daily volume of 153,100 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their price target on shares of NextCure from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, November 11th.

NextCure Price Performance

NASDAQ:NXTC traded down $0.00 during midday trading on Thursday, reaching $0.80. The stock had a trading volume of 42,777 shares, compared to its average volume of 129,641. NextCure has a 1-year low of $0.76 and a 1-year high of $2.57. The firm’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.28. The stock has a market capitalization of $22.30 million, a P/E ratio of -0.38 and a beta of 0.67.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). On average, equities research analysts anticipate that NextCure will post -1.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NextCure

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in NextCure by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after acquiring an additional 27,812 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in NextCure in the 4th quarter valued at about $311,000. Finally, Renaissance Technologies LLC grew its position in shares of NextCure by 15.4% during the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after buying an additional 61,744 shares during the period. 42.65% of the stock is owned by institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.